12
Participants
Start Date
November 7, 2019
Primary Completion Date
June 2, 2025
Study Completion Date
November 20, 2029
Intensity Modulated Radiation Therapy
-15 fractions of treatment
Carboplatin
Begins on day 1 of radiotherapy
MD Anderson Symptom Inventory (MDASI)-Plus module
The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
EuroQol (EQ-5D)
The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
SF-12
The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
MOS Social Support Measure
The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
CES-D
The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
Blood for ctDNA (optional)
-Collected at pre-treatment, every 2 weeks during chemoradiation, every 2-3 weeks during consolidation chemotherapy, completion of therapy, 6-8 week follow-up, 3 month follow-up, 6 month follow-up, and 12 month follow-up
Blood for SCCA
-Collected at pre-treatment, completion of therapy, and 6 month follow-up
Paclitaxel
Begins on day 1 of radiotherapy
Washington University School of Medicine, St Louis
Washington University School of Medicine
OTHER